Conditions: Prostate Cancer
Keywords: Abiraterone acetate
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 42
Healthy volunteers: no

Brief summary:
This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole.

It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Abiraterone acetate
Intervention descriptions: intervention 1: Abiraterone acetate 1000 mg by mouth per day

Protocol document: